Posters
Wavefront analysis and quality of vision in irregular corneas evaluated with Sirius CSO
Poster Details
First Author: M.Lecumberri SPAIN
Co Author(s): C. Moser M. Garat
Abstract Details
Purpose:
To describe wavefront analysis and quality of vision in different types of irregular corneas.
Setting:
Hospital Moises Broggi. Consorci Sanitari Integral. Barcelona (Spain).
Methods:
24 eyes of 12 patients with different corneal pathologies (16 eyes with Keratoconus, 4 of them with stromal ring segments, ,4 eyes with postlasik ectasia one of them cross linked, 2 eyes with corneal queratotomies and 2 eyes with previous DALK were evaluated with Sirius CSO. Patients were divided in 2 groups according to visual acuity: Group 1 (with BCVA ≥ 0.6) and Group 2 (with BCVA < 0.6), parameters of wavefront analysis and quality of vision: Root mean square (RMS), Higher order corneal aberrations (HOA) and Point spread function (PSF) were registered and compared in both groups.
Results:
In Group 1 mean RMS was 2,1914 IC 95% (0.8433-3,5394), mean HOA was 0.8828 IC95% (0,4772-1,288) and mean PFS was 0,2620 IC 95% (0,4772-1,2884). In Group 2 mean RMS was 3,36 IC 95% (2,78-3,93), mean HOA was 1,79 IC 95% (1,52.2,07) and mean PFS was 0,11 IC 95% (0,08-0,14).
Conclusions:
Patients with BCVA ≥ 0.6 had lower RMS, HOA and higher PFS. Parameters of Wavefront analysis and quality of vision obtained from Sirius CSO are useful to quantify quality of vision in irregular corneas
Financial Disclosure:
... gains financially from competing product or procedure, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... receives non-monetary benefits from a company producing, developing or supplying the product or procedure presented, ... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... is employed by a competing company, ... has significant investment interest in a company producing, developing or supplying product or procedure presented